The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to ...

Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading ...

Stocks are wavering in the early going on Wall Street at the start of a holiday-shortened week. The S&P 500 edged up 0.2% in ...

Ozempic has become a popular wonder drug among many Hollywood celebrities, who turned to the diabetes medication to lose ...

Zepbound was already approved and on the market ... while the Shanghai Composite index slipped 0.5% to 3,351.26. Australia's S&P/ASX 500 jumped 1.7% to 8,201.60. South Korea's Kospi added 1.6 ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

Following positive feedback from the Australian Competition and Consumer Commission ... earnings expectations whilst fending off concerns that weight-loss drugs like Zepbound may disrupt the sleep ...